Novo Nordisk A/S (NVO)
Listed on New York Stock Exchange • Healthcare / Drug Manufacturers - General
Overview
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Explore More Data
Key Information
Symbol:
NVO
CEO:
Lars Fruergaard Jorgensen
Exchange:
New York Stock Exchange
CIK:
0000353278
Website:
https://www.novonordisk.com
SEC Filings:
View SEC →
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Price
48.46
Change
0.21
Change %
0.44%
Open
46.98
Previous Close
48.25
High
49
Low
46.16
Volume
35,390,211
Market Cap
217,148,784,640
EV/EBITDA
8.22
Capital Structure (Updated: Nov 05 04:00 PM EST)
Shares Outstanding
3,368,558,040
FloatShares
3,187,938,882
Float Ratio
94.64%
Shares Short
26,671,758
Short Percent Of Float
The percent of float shares currently sold short. Reflects market sentiment and risk of a short squeeze.
0.79%
Short Ratio
Days needed to cover all short positions. Indicates short-selling pressure.
1.87 trading days
Held Percent Insiders
0.01%
Held Percent Institutions
8.81%
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date | 2025-11-05 |
| Earnings Call | 2025-11-05 |
| Avg EPS Estimate | 6.1067 |
| Low EPS Estimate | 5.71 |
| High EPS Estimate | 6.73 |
| Revenue | |
| Avg Revenue Forecast | 81,214,858,560 |
| Low Revenue Forecast | 78,623,000,000 |
| High Revenue Forecast | 82,695,000,000 |
NVO Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $18,933,999,616 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 0.505 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 0.784 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $99,268,001,792 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
NVO Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $159,260,999,680 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $121,527,001,088 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $26,440,624,128 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 84.26% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | 43.52% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | 35.61% | Net profit margin, which reflects overall profitability. |
NVO Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 59.06% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $99,268,001,792 | Used together with cash and EBITDA to assess debt-paying ability. |
NVO Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | 12.90% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 32.70% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for NVO (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $48.46 | Latest stock trading price |
| Price Target (High) | $70.58 | Analyst highest expected price |
| Price Target (Low) | $44.48 | Analyst lowest expected price |
| Price Target (Average) | $59.96 | Average target price across analysts |
| Price Target (Median) | $60.73 | Median of target prices |
| Average Rating Score | 2.18 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | buy | Consensus rating |
| Analyst Coverage Count | 9 | Number of analysts providing estimates |
| Cash Holdings | $18,933,999,616 | Total cash held by the company |
| Cash per Share | $4.26 | Cash value per outstanding share |
| Total Debt | $99,268,001,792 | Company's total debt |
| Quick Ratio | 0.505 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 0.784 | Overall short-term liquidity |
| Debt/Equity Ratio | 59.06% | Leverage ratio: Debt / Equity |
| EBITDA | $159,260,999,680 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $311,937,990,656 | Total company revenue |
| Revenue per Share | $70.144 | Total revenue divided by shares outstanding |
| Gross Profit | 84.26% | Revenue minus cost of goods sold |
| Return on Assets | 21.82% | Net income / Total assets |
| Return on Equity | 79.17% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 32.70% | Year-over-year EPS growth |
| Revenue Growth (YoY) | 12.90% | Year-over-year revenue growth |
| Gross Margin | 84.26% | Gross profit / Total revenue |
| EBITDA Margin | 51.06% | EBITDA / Revenue |
| Operating Margin | 43.52% | Operating income / Revenue |
| Profit Margin | 35.61% | Net income / Revenue |
| Free Cash Flow | $26,440,624,128 | Cash left after capital expenditures |
| Operating Cash Flow | $121,527,001,088 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |